Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

NCT03620643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Lobular Breast Carcinoma
Gastric Cancer
Triple Negative Breast Cancer
CDH1 Gene Mutation

Interventions

DRUG: Crizotinib Oral Capsule [Xalkori]
DRUG: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

[object Object]
[object Object]